Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286515948> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W4286515948 endingPage "S483" @default.
- W4286515948 startingPage "S483" @default.
- W4286515948 abstract "Regorafenib has been approved as a second-line treatment for advanced hepatocellular carcinoma (HCC), on the basis of the RESORCE trial. In the REORCE trial, patients with who tolerated sorafenib (≥400 mg/day for ≥20 of last 28 days of treatment) and progressed on sorafenib were enrolled. In clinical practice, sorafenib is often reduced due to various adverse events, yet the safety and efficacy of regorafenib in patients in whom sorafenib has been reduced to a lower dose is unclear. Furthermore, evidence is lacking on the safety and efficacy of regorafenib after administration of atezolizumab+bevacizumab (Atezo/Bev) and lenvatinib, which are current standard first-line treatments." @default.
- W4286515948 created "2022-07-22" @default.
- W4286515948 creator A5006189074 @default.
- W4286515948 creator A5014348565 @default.
- W4286515948 creator A5016927438 @default.
- W4286515948 creator A5022431851 @default.
- W4286515948 creator A5038679040 @default.
- W4286515948 creator A5041139736 @default.
- W4286515948 creator A5042700054 @default.
- W4286515948 creator A5045756401 @default.
- W4286515948 creator A5046469956 @default.
- W4286515948 creator A5047431198 @default.
- W4286515948 creator A5047879551 @default.
- W4286515948 creator A5050720566 @default.
- W4286515948 creator A5052154025 @default.
- W4286515948 creator A5055585512 @default.
- W4286515948 creator A5066017229 @default.
- W4286515948 creator A5069538041 @default.
- W4286515948 creator A5071754450 @default.
- W4286515948 creator A5071892047 @default.
- W4286515948 creator A5073943213 @default.
- W4286515948 creator A5083755934 @default.
- W4286515948 date "2022-07-01" @default.
- W4286515948 modified "2023-10-16" @default.
- W4286515948 title "MO5-1 Regorafenib in advanced HCC patients who were not included in the RESORCE trial: first interim analysis" @default.
- W4286515948 doi "https://doi.org/10.1016/j.annonc.2022.05.107" @default.
- W4286515948 hasPublicationYear "2022" @default.
- W4286515948 type Work @default.
- W4286515948 citedByCount "0" @default.
- W4286515948 crossrefType "journal-article" @default.
- W4286515948 hasAuthorship W4286515948A5006189074 @default.
- W4286515948 hasAuthorship W4286515948A5014348565 @default.
- W4286515948 hasAuthorship W4286515948A5016927438 @default.
- W4286515948 hasAuthorship W4286515948A5022431851 @default.
- W4286515948 hasAuthorship W4286515948A5038679040 @default.
- W4286515948 hasAuthorship W4286515948A5041139736 @default.
- W4286515948 hasAuthorship W4286515948A5042700054 @default.
- W4286515948 hasAuthorship W4286515948A5045756401 @default.
- W4286515948 hasAuthorship W4286515948A5046469956 @default.
- W4286515948 hasAuthorship W4286515948A5047431198 @default.
- W4286515948 hasAuthorship W4286515948A5047879551 @default.
- W4286515948 hasAuthorship W4286515948A5050720566 @default.
- W4286515948 hasAuthorship W4286515948A5052154025 @default.
- W4286515948 hasAuthorship W4286515948A5055585512 @default.
- W4286515948 hasAuthorship W4286515948A5066017229 @default.
- W4286515948 hasAuthorship W4286515948A5069538041 @default.
- W4286515948 hasAuthorship W4286515948A5071754450 @default.
- W4286515948 hasAuthorship W4286515948A5071892047 @default.
- W4286515948 hasAuthorship W4286515948A5073943213 @default.
- W4286515948 hasAuthorship W4286515948A5083755934 @default.
- W4286515948 hasBestOaLocation W42865159481 @default.
- W4286515948 hasConcept C121608353 @default.
- W4286515948 hasConcept C126322002 @default.
- W4286515948 hasConcept C143998085 @default.
- W4286515948 hasConcept C166957645 @default.
- W4286515948 hasConcept C2776248978 @default.
- W4286515948 hasConcept C2776957806 @default.
- W4286515948 hasConcept C526805850 @default.
- W4286515948 hasConcept C535046627 @default.
- W4286515948 hasConcept C61943457 @default.
- W4286515948 hasConcept C71924100 @default.
- W4286515948 hasConcept C95457728 @default.
- W4286515948 hasConceptScore W4286515948C121608353 @default.
- W4286515948 hasConceptScore W4286515948C126322002 @default.
- W4286515948 hasConceptScore W4286515948C143998085 @default.
- W4286515948 hasConceptScore W4286515948C166957645 @default.
- W4286515948 hasConceptScore W4286515948C2776248978 @default.
- W4286515948 hasConceptScore W4286515948C2776957806 @default.
- W4286515948 hasConceptScore W4286515948C526805850 @default.
- W4286515948 hasConceptScore W4286515948C535046627 @default.
- W4286515948 hasConceptScore W4286515948C61943457 @default.
- W4286515948 hasConceptScore W4286515948C71924100 @default.
- W4286515948 hasConceptScore W4286515948C95457728 @default.
- W4286515948 hasLocation W42865159481 @default.
- W4286515948 hasOpenAccess W4286515948 @default.
- W4286515948 hasPrimaryLocation W42865159481 @default.
- W4286515948 hasRelatedWork W2058040569 @default.
- W4286515948 hasRelatedWork W2065054494 @default.
- W4286515948 hasRelatedWork W2289658055 @default.
- W4286515948 hasRelatedWork W2339196520 @default.
- W4286515948 hasRelatedWork W2588643499 @default.
- W4286515948 hasRelatedWork W2598448479 @default.
- W4286515948 hasRelatedWork W2769365968 @default.
- W4286515948 hasRelatedWork W3047792918 @default.
- W4286515948 hasRelatedWork W3085278910 @default.
- W4286515948 hasRelatedWork W3088753604 @default.
- W4286515948 hasVolume "33" @default.
- W4286515948 isParatext "false" @default.
- W4286515948 isRetracted "false" @default.
- W4286515948 workType "article" @default.